Browsing by Author Paz-Ares, Luis

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 4 of 4
Issue DateTitleAuthor(s)Citation
2017Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trialBoyer, Michael; et al, Various; Hirsh, Vera; Lee, Ki Hyeong; Lu, Shun; Mok, Tony; O'Byrne, Kenneth J.; Paz-Ares, Luis; Tan, Eng Huat; Yang, James Chic-Hsin; Zhang, Li; Central Clinical School: MedicineAfatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial, Annals of Oncology, vol.28, 2, 2017,pp 270-277
2016Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trialsBoyer, Michael; Janne, P. A.; Liang, Jane Q.; Mok, T. S. K.; O'Byrne, Kenneth; Paz-Ares, Luis; Ramalingam, Suresh; Sbar, E. I.; Taylor, I.; Zhang, H.; Central Clinical School: MedicineDacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials, Annals of Oncology, vol.27, 3, 2016,pp 423-429
2011Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung CancerBoyer, Michael; Bajetta, Emilio; Benner, Rebecca J.; Eberhardt, Wilfried E. E.; et al, various; Hirsh, V; Paz-Ares, Luis; Raats, Johannes; Reiterer, Pavel; Rosell, Rafael Costa; Saleh, Mansoor; Szczesna, Aleksandra; Webb, Roy T.; Central Clinical School: MedicineRandomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.29, 19, 2011,pp 2667-2674
2010Vandetanib (100 mg) in Patients with Locally Advanced or Metastatic Hereditary Medullary Thyroid CancerRobinson, Bruce; Haddad, Robert; Krebs, Annetta; Paz-Ares, Luis; Vasselli, James; Northern Clinical School: MedicineVandetanib (100 mg) in Patients with Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer, Journal of Clinical Endocrinology and Metabolism, vol.95, 6, 2010,pp 2664-2671